{"filing":{"accession_number":"0001104659-26-106836","cik":"0001702123","ticker":"CRDL","company_name":"Cardiol Therapeutics Inc.","form":"6-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"tm2625221d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1702123/000110465926106836/tm2625221d1_6k.htm"},"events":[{"id":32777,"run_id":30136,"accession_number":"0001104659-26-106836","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Cardiol Therapeutics entered into an Exclusive Master Services Agreement with Dalton Chemical Laboratories (Dalton Pharma Services) dated April 17, 2018, establishing an exclusive manufacturing and pharmaceutical services relationship covering API development, formulation, synthesis, and manufacturing, with equity consideration to Dalton.","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":[{"id":36036,"accession_number":"0001104659-26-106836","item_number":"EX-99.1","item_title":"tm2625221d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is an Exclusive Master Services Agreement between Cardiol Therapeutics Inc. and Dalton Chemical Laboratories (Dalton Pharma Services) dated April 17, 2018, effective June 12, 2017. The agreement establishes an exclusive manufacturing and pharmaceutical services relationship covering API development, formulation, synthesis, manufacturing, and related services. Section 2.1 grants Dalton exclusivity in the Field in exchange for share issuance to Dalton (Appendix B). This is a material operational/strategic contract establishing a long-term exclusive supplier relationship with equity consideration, which would affect a reasonable investor's assessment of the company's supply chain and capital structure, though it does not fit neatly into the discrete event categories (M\u0026A, debt, dilution, etc.) and is best classified as a material operational contract or partnership arrangement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32778,"run_id":30136,"accession_number":"0001104659-26-106836","anchor_item_number":"EX-99.2","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"summary":"Cardiol Therapeutics furnished a development agreement with CARO (Clinical Academic Research Organization) dated August 29, 2018, governing research and development collaboration for heart failure drug formulations with compensation via warrants and shares.","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":[{"id":36037,"accession_number":"0001104659-26-106836","item_number":"EX-99.2","item_title":"tm2625221d1_ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This exhibit is a development agreement between Cardiol Therapeutics and CARO (Clinical Academic Research Organization) dated August 29, 2018, governing research and development collaboration for drug formulations targeting heart failure. The document establishes terms for development activities, compensation via warrants and shares, regulatory responsibilities, and intellectual property management. While the agreement itself is a material contract, this exhibit appears to be a historical document being furnished as part of a 6-K filing (likely in connection with a later corporate event or disclosure requirement). The agreement itself does not disclose a new material event occurring at the filing date (September 10, 2026); rather, it is a supporting exhibit to a 6-K. Absent evidence that this agreement is being newly entered into, amended, or terminated at the filing date, it is classified as an operational contract disclosure that does not constitute a discrete material event requiring immediate investor attention.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32779,"run_id":30136,"accession_number":"0001104659-26-106836","anchor_item_number":"EX-99.7","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Cardiol Therapeutics entered into Amendment No. 6 to an exclusive supply agreement with Noramco for active pharmaceutical ingredient supply, modifying minimum purchase quantities and pricing terms, and conditioning retail exclusivity in Canada and Mexico on Cardiol entering into a supply agreement with Shoppers Drug Mart by May 31, 2020.","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":[{"id":36042,"accession_number":"0001104659-26-106836","item_number":"EX-99.7","item_title":"tm2625221d1_ex99-7.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit discloses Amendment No. 6 to an exclusive supply agreement between Cardiol Therapeutics and Noramco for active pharmaceutical ingredient (API) supply. The amendment modifies minimum purchase quantities and pricing terms, and conditions retail exclusivity in Canada and Mexico on Cardiol entering into a supply agreement with Shoppers Drug Mart by May 31, 2020. This is a material operational/commercial arrangement affecting Cardiol's supply chain and market exclusivity rights, but does not fit the specific event categories (M\u0026A, debt, litigation, etc.); it is a material contract modification that would affect investor assessment of the company's business relationships and market position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32780,"run_id":30136,"accession_number":"0001104659-26-106836","anchor_item_number":"EX-99.3","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"summary":"Cardiol Therapeutics furnished routine amendments and administrative modifications to its exclusive supply agreement with Noramco, including minor deadline adjustments and payment schedule extensions dated between December 2018 and October 2019.","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":[{"id":36038,"accession_number":"0001104659-26-106836","item_number":"EX-99.3","item_title":"tm2625221d1_ex99-3.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This exhibit is an amendment to an exclusive supply agreement between Cardiol Therapeutics and Noramco, Inc., dated December 7, 2018. The amendment makes a minor modification to the exclusivity provision, changing a deadline from December 1, 2018 to December 21, 2018. This is a routine contractual amendment that does not disclose a material business event, strategic partnership, or operational milestone that would affect a reasonable investor's assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36039,"accession_number":"0001104659-26-106836","item_number":"EX-99.4","item_title":"tm2625221d1_ex99-4.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This exhibit is Amendment No. 3 to an Exclusive Supply Agreement between Cardiol Therapeutics and Noramco, Inc., modifying payment terms and timelines for raw materials purchases ($1.2M each on September 15, 2019 and November 30, 2019). While supply agreements are operational in nature, this amendment merely adjusts payment schedules for an existing supplier relationship and does not disclose a material new contract, partnership, or strategic milestone that would affect a reasonable investor's assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36040,"accession_number":"0001104659-26-106836","item_number":"EX-99.5","item_title":"tm2625221d1_ex99-5.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This exhibit is Amendment No. 4 to an Exclusive Supply Agreement between Cardiol Therapeutics and Noramco, modifying payment terms and timelines for raw materials purchases ($1.2M each on September 22, 2019 and November 30, 2019 for 700KG of API). While supply agreements are operational in nature, this amendment merely adjusts payment schedules on an existing supplier relationship and does not disclose a material strategic event, new material contract, or significant business development that would affect a reasonable investor's assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36041,"accession_number":"0001104659-26-106836","item_number":"EX-99.6","item_title":"tm2625221d1_ex99-6.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This is a payment extension agreement between Cardiol and its raw-materials supplier Noramco, dated October 28, 2019, extending two payment deadlines under an existing Exclusive Supply Agreement to November 2019. The document is a routine amendment to a commercial supply contract, extending payment timelines by approximately one month. While supply-chain continuity is operationally relevant, a short-term payment deferral on raw-material purchases is administrative and would not materially affect a reasonable investor's assessment of the registrant's financial condition or prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32781,"run_id":30136,"accession_number":"0001104659-26-106836","anchor_item_number":"EX-99.8","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.72,"summary":"Cardiol Therapeutics furnished notice of assignment of an Exclusive Supply Agreement from Noramco, Inc. to Purisys LLC (an affiliate of Noramco), effective December 30, 2019, representing a routine contractual transfer between related entities.","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":[{"id":36043,"accession_number":"0001104659-26-106836","item_number":"EX-99.8","item_title":"tm2625221d1_ex99-8.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.72,"reasoning":"This exhibit is a notice of assignment of an Exclusive Supply Agreement dated September 28, 2018, from Noramco, Inc. to Purisys LLC (an affiliate of Noramco), effective December 30, 2019. The assignment is a routine contractual transfer between related entities and does not disclose a material change in the registrant's business operations, financial condition, or strategic direction. The supply agreement itself predates this filing by years, and the assignment to an affiliate does not materially alter Cardiol's rights or obligations under the contract.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36036,"accession_number":"0001104659-26-106836","item_number":"EX-99.1","item_title":"tm2625221d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is an Exclusive Master Services Agreement between Cardiol Therapeutics Inc. and Dalton Chemical Laboratories (Dalton Pharma Services) dated April 17, 2018, effective June 12, 2017. The agreement establishes an exclusive manufacturing and pharmaceutical services relationship covering API development, formulation, synthesis, manufacturing, and related services. Section 2.1 grants Dalton exclusivity in the Field in exchange for share issuance to Dalton (Appendix B). This is a material operational/strategic contract establishing a long-term exclusive supplier relationship with equity consideration, which would affect a reasonable investor's assessment of the company's supply chain and capital structure, though it does not fit neatly into the discrete event categories (M\u0026A, debt, dilution, etc.) and is best classified as a material operational contract or partnership arrangement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10"},{"id":36037,"accession_number":"0001104659-26-106836","item_number":"EX-99.2","item_title":"tm2625221d1_ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This exhibit is a development agreement between Cardiol Therapeutics and CARO (Clinical Academic Research Organization) dated August 29, 2018, governing research and development collaboration for drug formulations targeting heart failure. The document establishes terms for development activities, compensation via warrants and shares, regulatory responsibilities, and intellectual property management. While the agreement itself is a material contract, this exhibit appears to be a historical document being furnished as part of a 6-K filing (likely in connection with a later corporate event or disclosure requirement). The agreement itself does not disclose a new material event occurring at the filing date (September 10, 2026); rather, it is a supporting exhibit to a 6-K. Absent evidence that this agreement is being newly entered into, amended, or terminated at the filing date, it is classified as an operational contract disclosure that does not constitute a discrete material event requiring immediate investor attention.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10"},{"id":36038,"accession_number":"0001104659-26-106836","item_number":"EX-99.3","item_title":"tm2625221d1_ex99-3.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This exhibit is an amendment to an exclusive supply agreement between Cardiol Therapeutics and Noramco, Inc., dated December 7, 2018. The amendment makes a minor modification to the exclusivity provision, changing a deadline from December 1, 2018 to December 21, 2018. This is a routine contractual amendment that does not disclose a material business event, strategic partnership, or operational milestone that would affect a reasonable investor's assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10"},{"id":36039,"accession_number":"0001104659-26-106836","item_number":"EX-99.4","item_title":"tm2625221d1_ex99-4.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This exhibit is Amendment No. 3 to an Exclusive Supply Agreement between Cardiol Therapeutics and Noramco, Inc., modifying payment terms and timelines for raw materials purchases ($1.2M each on September 15, 2019 and November 30, 2019). While supply agreements are operational in nature, this amendment merely adjusts payment schedules for an existing supplier relationship and does not disclose a material new contract, partnership, or strategic milestone that would affect a reasonable investor's assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10"},{"id":36040,"accession_number":"0001104659-26-106836","item_number":"EX-99.5","item_title":"tm2625221d1_ex99-5.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This exhibit is Amendment No. 4 to an Exclusive Supply Agreement between Cardiol Therapeutics and Noramco, modifying payment terms and timelines for raw materials purchases ($1.2M each on September 22, 2019 and November 30, 2019 for 700KG of API). While supply agreements are operational in nature, this amendment merely adjusts payment schedules on an existing supplier relationship and does not disclose a material strategic event, new material contract, or significant business development that would affect a reasonable investor's assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10"},{"id":36041,"accession_number":"0001104659-26-106836","item_number":"EX-99.6","item_title":"tm2625221d1_ex99-6.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"This is a payment extension agreement between Cardiol and its raw-materials supplier Noramco, dated October 28, 2019, extending two payment deadlines under an existing Exclusive Supply Agreement to November 2019. The document is a routine amendment to a commercial supply contract, extending payment timelines by approximately one month. While supply-chain continuity is operationally relevant, a short-term payment deferral on raw-material purchases is administrative and would not materially affect a reasonable investor's assessment of the registrant's financial condition or prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10"},{"id":36042,"accession_number":"0001104659-26-106836","item_number":"EX-99.7","item_title":"tm2625221d1_ex99-7.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit discloses Amendment No. 6 to an exclusive supply agreement between Cardiol Therapeutics and Noramco for active pharmaceutical ingredient (API) supply. The amendment modifies minimum purchase quantities and pricing terms, and conditions retail exclusivity in Canada and Mexico on Cardiol entering into a supply agreement with Shoppers Drug Mart by May 31, 2020. This is a material operational/commercial arrangement affecting Cardiol's supply chain and market exclusivity rights, but does not fit the specific event categories (M\u0026A, debt, litigation, etc.); it is a material contract modification that would affect investor assessment of the company's business relationships and market position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10"},{"id":36043,"accession_number":"0001104659-26-106836","item_number":"EX-99.8","item_title":"tm2625221d1_ex99-8.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.72,"reasoning":"This exhibit is a notice of assignment of an Exclusive Supply Agreement dated September 28, 2018, from Noramco, Inc. to Purisys LLC (an affiliate of Noramco), effective December 30, 2019. The assignment is a routine contractual transfer between related entities and does not disclose a material change in the registrant's business operations, financial condition, or strategic direction. The supply agreement itself predates this filing by years, and the assignment to an affiliate does not materially alter Cardiol's rights or obligations under the contract.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:08.481039+00:00","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10"}]}